Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. May 15, 2025; 17(5): 104341
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.104341
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.104341
Table 1 Baseline demographic and clinical characteristics of patients according to tumor marker index groups, n (%)
Total (n = 305) | TMI-low (n = 151) | TMI-high (n = 154) | P value | |
Age, mean ± SD | 64.5 ± 12.4 | 64.1 ± 12.8 | 64.9 ± 12.0 | 0.56a |
≤ 65 years | 150 (49.2) | 76 (50.3) | 74 (48.1) | 0.69b |
> 65 years | 155 (50.8) | 75 (49.7) | 80 (51.9) | |
Sex | ||||
Female | 113 (37.0) | 58 (38.4) | 55 (35.7) | 0.63b |
Male | 192 (63.0) | 93 (61.6) | 99 (64.3) | |
ECOG-PS | ||||
0 | 108 (35.4) | 54 (35.8) | 54 (35.1) | 0.18c |
1 | 156 (51.1) | 83 (55) | 73 (47.4) | |
2 | 36 (11.8) | 12 (7.9) | 24 (15.6) | |
3 | 5 (1.6) | 2 (1.3) | 3 (1.9) | |
BMI | ||||
≤ 25 kg/m2 | 201 (65.9) | 109 (72.2) | 92 (59.7) | 0.02b |
> 25 kg/m2 | 104 (34.1) | 42 (27.8) | 62 (40.3) | |
Smoking history | ||||
No | 172 (56.4) | 81 (53.6) | 91 (59.1) | 0.34b |
Yes | 133 (43.6) | 70 (46.4) | 63 (40.9) | |
Alcohol using | ||||
No | 280 (91.8) | 138 (91.4) | 142 (92.2) | 0.79b |
Yes | 25 (8.2) | 13 (8.6) | 12 (7.8) | |
DM | ||||
No | 244 (80.0) | 123 (81.5) | 121 (78.6) | 0.53b |
Yes | 61 (20.0) | 28 (18.5) | 33 (21.4) | |
HT | ||||
No | 199 (65.2) | 102 (67.5) | 97 (63) | 0.40b |
Yes | 106 (34.8) | 49 (32.5) | 57 (37) | |
CAD | ||||
No | 265 (86.9) | 132 (87.4) | 133 (86.4) | 0.78b |
Yes | 40 (13.1) | 19 (12.6) | 21 (13.6) | |
Disease status | ||||
De-novo metastatic | 209 (68.5) | 96 (63.6) | 113 (73.4) | 0.06b |
Recurrent metastatic | 96 (31.5) | 55 (36.4) | 41 (26.6) | |
History of adjuvant CT | ||||
No | 206 (67.5) | 94 (62.3) | 112 (72.7) | 0.05b |
Yes | 99 (32.5) | 57 (37.7) | 42 (27.3) | |
Liver metastasis | ||||
No | 92 (31.2) | 56 (37.1) | 36 (23.4) | 0.01b |
Yes | 213 (69.8) | 95 (62.9) | 118 (76.6) | |
Lung metastasis | ||||
No | 201 (65.9) | 104 (68.9) | 97 (63) | 0.28b |
Yes | 104 (34.1) | 47 (31.1) | 57 (37) | |
Bone metastasis | ||||
No | 281 (92.1) | 142 (94) | 139 (90.3) | 0.22b |
Yes | 24 (7.9) | 9 (6) | 15 (9.7) | |
Peritoneal metastasis | ||||
No | 233 (76.4) | 106 (70.2) | 127 (82.5) | 0.01b |
Yes | 72 (23.6) | 45 (29.8) | 27 (17.5) | |
Number of metastatic site | ||||
1 | 157 (51.5) | 80 (53) | 77 (50) | 0.35b |
2 | 91 (29.8) | 48 (31.8) | 43 (27.9) | |
3 | 38 (12.5) | 17 (11.3) | 21 (13.6) | |
4 or more | 19 (6.2) | 6 (4) | 13 (8.4) | |
Isolated liver metastasis | ||||
No | 207 (67.9) | 106 (70.2) | 101 (65.6) | 0.39b |
Yes | 98 (32.1) | 45 (29.8) | 53 (34.4) | |
History of metastasectomy | ||||
No | 242 (79.3) | 110 (72.8) | 132 (85.7) | 0.006b |
Yes | 63 (20.7) | 41 (27.2) | 22 (14.3) | |
Tumor location | ||||
Right side colon cancer | 65 (21.3) | 27 (17.9) | 38 (24.7) | 0.29b |
Left side colon cancer | 140 (45.9) | 70 (46.4) | 70 (45.5) | |
Rectum cancer | 100 (32.8) | 54 (35.8) | 46 (29.9) | |
KRAS | ||||
Wild | 182 (59.7) | 98 (64.9) | 84 (54.5) | 0.02b |
Mutant | 93 (30.5) | 35 (23.2) | 58 (37.7) | |
Unknown | 30 (9.8) | 18 (11.9) | 12 (7.8) | |
NRAS | ||||
Wild | 236 (77.4) | 114 (75.5) | 122 (79.2) | 0.26b |
Mutant | 20 (6.6) | 8 (5.3) | 12 (7.8) | |
Unknown | 49 (16.1) | 29 (19.2) | 20 (13) | |
BRAF | ||||
Wild | 241 (79.0) | 118 (78.1) | 123 (79.9) | 0.79b |
Mutant | 10 (3.3) | 6 (4) | 4 (2.6) | |
Unknown | 54 (17.7) | 27 (17.9) | 27 (17.5) | |
MSI status | ||||
Microsatellite stable | 183 (60.0) | 85 (56.3) | 98 (63.6) | 0.42b |
MSI-high | 11 (3.6) | 6 (4) | 5 (3.2) | |
Unknown | 111 (36.4) | 60 (39.7) | 51 (33.1) | |
Metastatic line(s) of CT | ||||
1 | 120 (40.0) | 61 (40.9) | 59 (39.1) | 0.66b |
2 | 87 (29.0) | 46 (30.9) | 41 (27.2) | |
3 | 41 (13.7) | 17 (11.4) | 24 (15.9) | |
4 and more | 52 (17.3) | 25 (16.8) | 27 (17.9) | |
Using immunotherapy | ||||
No | 302 (99.0) | 150 (99.3) | 152 (98.7) | 0.99c |
Yes | 3 (1.0) | 1 (0.7) | 2 (1.3) | |
GPS | ||||
0 | 134 (43.9) | 78 (51.7) | 56 (36.4) | 0.03b |
1 | 132 (43.3) | 57 (37.7) | 75 (48.7) | |
2 | 39 (12.8) | 16 (10.6) | 23 (14.9) | |
NLR, mean ± SD | 3.45 ± 2.55 | 3.15 ± 1.98 | 3.76 ± 2.98 | 0.04c |
- Citation: Ilhan Y, Balcik OY, Guzel HG, Onder AH, Demir B, Baser MN, Karadag I, Ozbay MF, Genc TB, Uzuntas S, Poyrazoglu O, Beypinar I, Ergun Y, Ozturk B. Novel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer. World J Gastrointest Oncol 2025; 17(5): 104341
- URL: https://www.wjgnet.com/1948-5204/full/v17/i5/104341.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i5.104341